| A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. | |
| | |
MedLine Citation:
|
PMID: 20631323 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dietary fat intake plays a critical role in the development of metabolic syndrome (MetS). This study addressed the hypothesis that dietary fat quantity and quality may differentially modulate postprandial lipoprotein metabolism in MetS patients. A multi-center, parallel, randomized, controlled trial conducted within the LIPGENE study randomly assigned MetS patients to 1 of 4 diets: high-SFA [HSFA; 38% energy (E) from fat, 16% E as SFA], high-monounsaturated fatty acid [HMUFA; 38% E from fat, 20% E as MUFA], and 2 low-fat, high-complex carbohydrate [LFHCC; 28% E from fat] diets supplemented with 1.24 g/d of long-chain (LC) (n-3) PUFA (ratio 1.4 eicosapentaenoic acid:1 docosahexaenoic acid) or placebo (1.24 g/d of high-oleic sunflower-seed oil) for 12 wk each. A fat challenge with the same fat composition as the diets was conducted pre- and postintervention. Postprandial total cholesterol, triglycerides (TG), apolipoprotein (apo) B, apo B-48, apo A-I, LDL-cholesterol, HDL-cholesterol and cholesterol, TG, retinyl palmitate, and apo B in TG-rich lipoproteins (TRL; large and small) were determined pre- and postintervention. Postintervention, postprandial TG (P < 0.001) and large TRL-TG (P = 0.009) clearance began earlier and was faster in the HMUFA group compared with the HSFA and LFHCC groups. The LFHCC (n-3) group had a lower postprandial TG concentration (P < 0.001) than the other diet groups. Consuming the LFHCC diet increased the TG (P = 0.04), large TRL-TG (P = 0.01), TRL-cholesterol (P < 0.001), TRL-retinyl palmitate (P = 0.001), and TRL-apo B (P = 0.002) area under the curve compared with preintervention values. In contrast, long-term ingestion of the LFHCC (n-3) diet did not augment postprandial TG and TRL metabolism. In conclusion, postprandial abnormalities associated with MetS can be attenuated with LFHCC (n-3) and HMUFA diets. The adverse postprandial TG-raising effects of long-term LFHCC diets may be avoided by concomitant LC (n-3) PUFA supplementation to weight-stable MetS patients. |
| | |
Authors:
|
Yolanda Jiménez-Gómez; Carmen Marín; Pablo Peérez-Martínez; Jadwiga Hartwich; Malgorzata Malczewska-Malec; Iwona Golabek; Beata Kiec-Wilk; Cristina Cruz-Teno; Fernando Rodríguez; Purificación Gómez; Maria J Gómez-Luna; Catherine Defoort; Michael J Gibney; Francisco Pérez-Jiménez; Helen M Roche; José López-Miranda |
Related Documents
:
|
10197313 - Evaluation of fasting serum insulin levels among japanese school-age children. 4074463 - High density lipoprotein cholesterol, habitual physical activity and physical fitness. 15935403 - High-fat diet induces increased tissue expression of tnf-alpha. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-07-14 |
Journal Detail:
|
Title: The Journal of nutrition Volume: 140 ISSN: 1541-6100 ISO Abbreviation: J. Nutr. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-23 Completed Date: 2010-09-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0404243 Medline TA: J Nutr Country: United States |
Other Details:
|
Languages: eng Pagination: 1595-601 Citation Subset: IM |
Affiliation:
|
Reina Sofía University Hospital, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00429195 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Dietary Carbohydrates
/
administration & dosage,
pharmacology* Dietary Fats / administration & dosage, pharmacology* Docosahexaenoic Acids / administration & dosage, pharmacology* Eicosapentaenoic Acid / administration & dosage, pharmacology* Female Humans Lipids / blood Lipoproteins / blood*, metabolism Male Metabolic Syndrome X / blood, diet therapy* Middle Aged Postprandial Period / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Dietary Carbohydrates; 0/Dietary Fats; 0/Lipids; 0/Lipoproteins; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Seeking congruity between goals and roles: a new look at why women opt out of science, technology, e...
Next Document: Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human br...